Literature DB >> 9353652

Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion.

W B Brouwer1, M A Koopmanschap, F F Rutten.   

Abstract

In this response we concentrate on what Weinstein et al. call the 'major disagreement' between the Erasmus group and the US Panel, which concerns the measurement of productivity losses during illness. We consider the consequences for the individual, for the employer and for the rest of society and argue that when following the Panel's propositions for measuring these consequences, major theoretical and practical difficulties are encountered.

Mesh:

Year:  1997        PMID: 9353652     DOI: 10.1002/(sici)1099-1050(199709)6:5<511::aid-hec297>3.0.co;2-k

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  32 in total

Review 1.  Understanding cost effectiveness: a detailed review.

Authors:  A F Smith; G C Brown
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

Review 2.  Resource allocation, social values and the QALY: a review of the debate and empirical evidence.

Authors:  David L B Schwappach
Journal:  Health Expect       Date:  2002-09       Impact factor: 3.377

3.  The friction-cost method : replacement for nothing and leisure for free?

Authors:  Werner B F Brouwer; Marc A Koopmanschap
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  The relationship between productivity and health-related QOL: an exploration.

Authors:  Werner B F Brouwer; Willem-Jan Meerding; Leida M Lamers; Johan L Severens
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  Introducing economic evaluation as a policy tool in Korea: will decision makers get quality information? : a critical review of published Korean economic evaluations.

Authors:  Kun-Sei Lee; Werner B F Brouwer; Sang-Il Lee; Hye-Won Koo
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

6.  Productivity costs in health-state valuations : does explicit instruction matter?

Authors:  Marieke Krol; Werner Brouwer; Pedram Sendi
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

7.  Measuring time costs in interventions designed to reduce behavior problems among children and youth.

Authors:  E Michael Foster; Deborah Johnson-Shelton; Ted K Taylor
Journal:  Am J Community Psychol       Date:  2007-09

8.  Predicting productivity based on EQ-5D: an explorative study.

Authors:  Marieke Krol; Elly Stolk; Werner Brouwer
Journal:  Eur J Health Econ       Date:  2013-06-13

Review 9.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 10.  Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.

Authors:  Christian Krauth; Noushin Jalilvand; Tobias Welte; Reinhard Busse
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.